Crossmark

ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing Neoadjuvant Therapy

Crossref DOI link: https://doi.org/10.1245/s10434-025-17536-x

Published Online: 2025-05-28

Published Print: 2025-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jacover, Arielle

Pencovich, Niv
Funding

Funding for this research was provided by:

Tel Aviv University
License Information

Text and Data Mining valid from 2025-05-28

Version of Record valid from 2025-05-28
More Information

Article History

Received: 29 April 2025

Accepted: 3 May 2025

First Online: 28 May 2025

Disclosures

: The authors declare no conflict of interest. Talia Golan reports receipt of grants/research supports from AstraZeneca and Abbvie; receipt of honoraria or consultation fees from Abbvie, MSD, and Merck; receipt of speaker’s bureau from Abbvie and ClearNote Health Royalties; and is a consultant for Curesponse.

Document is current

Any future updates will be listed below